Graphene Manufacturing Group Announces Pricing of Marketed Unit Offering

In This Article:

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Base Shelf Prospectus Accessible and Prospectus Supplement to be Accessible on SEDAR+

BRISBANE, Australia, April 26, 2024 (GLOBE NEWSWIRE) -- Graphene Manufacturing Group Ltd. (TSX-V: GMG) (“GMG” or the “Company”) is pleased to announce pricing of its previously announced marketed offering (the “Offering”) of units (the “Units”) of the Company. In connection with the Offering, the Company intends to enter into an underwriting agreement dated April 26, 2024 (the “Underwriting Agreement”) with PI Financial Corp. as sole underwriter and bookrunner for the Offering (the “Underwriter”).

Pursuant to the Underwriting Agreement, the Company will issue 4,762,000 Units at a price of $0.42 per Unit for aggregate gross proceeds to the Company of approximately $2,000,040. Each Unit will consist of one ordinary share of the Company (a “Common Share”) and one ordinary share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (each a “Warrant Share”) at an exercise price of $0.55 per Warrant Share for a period of 4 years following the closing of the Offering, subject to adjustment in certain events.

The Units will be offered under the amended and restated base shelf prospectus of the Company receipted on January 10, 2024 (the “Base Shelf Prospectus”), as supplemented by a prospectus supplement (the “Supplement”) to be prepared and filed in each of the provinces and territories of Canada other than Quebec (collectively, the “Jurisdictions”) and in the United States pursuant to available exemptions from the registration requirements under applicable United States securities laws, and in such other jurisdictions outside of Canada and the United States which are agreed to by the Company and the Underwriter.

Pursuant to the Underwriting Agreement, the Company has granted the Underwriter an option (the “Over-Allotment Option”) to cover over-allotments and for market stabilization purposes. The Over-Allotment Option may be exercised at any time up to 30 days subsequent to the closing of the Offering to purchase up to an additional 15.0% of the Units sold under the Offering on the same terms and conditions of the Offering. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriter.

The net proceeds of the Offering are expected to be used primarily to strengthen the Company's financial position and provide liquidity to ?finance ongoing operations, including, in particular, the Company’s expenses incurred, and expected to be ?incurred, in connection with the Company’s research and development objectives, and for working capital and general corporate purposes.